Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma

Table 2

Reported cases of docetaxel-induced SJS.

Author	Year	Type of article	Description of case/study	Outcome
Moisidis and Möbus [1]	2005	Case report	76-year-old female with metastatic breast cancer with docetaxel-induced erythema multiforme	Resolution of symptoms after 3 weeks following treatment with high-dose steroids
Dourakis et al. [5]	2002	Case report	60-year-old patient with non-Hodgkin’s lymphoma and received salvage therapy with docetaxel and prednisone developed SJS within 5 days of treatment	Received treatment with supportive measures and survived
Arshad et al. [6]	2014	Case report	46-year-old female with metastatic breast cancer developed SJS two weeks following treatment with three cycles of docetaxel.	She was supportively managed.
Sawada et al. [7]	2009	Case report	56-year-old female treated for metastatic breast cancer with first cycle of docetaxel developed SJS.	She received treatment with topical clobetasol and triamcinolone and other supportive measures. The patient survived with resolution of symptoms.
Ohlmann et al. [8]	2007	Case report	67-year-old male with prostate cancer received docetaxel as a part of a randomized phase III trial developed SJS after five cycles of treatment.	Patient received systemic steroids and antibiotics for treatment and succumbed as a result of SJS secondary to docetaxel.
Kattan et al. [9]	2008	Clinical trial, open-labelled phase II	27 patients received weekly docetaxel and zoledronic acid and estramustine between 2002 and 2014 for hormone refractory prostate cancer.	1 patient died of docetaxel toxicity in the form of SJS, 2 weeks after the second cycle.